|
시장보고서
상품코드
2067550
감염증 면역측정 검사 시장 규모, 점유율 및 동향 분석 보고서 : 질환별, 기술별, 검사 종별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Infectious Disease Immunoassay Testing Market Size, Share & Trends Analysis Report By Disease Type, By Technology, By Test Type, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
감염병 면역측정 검사 시장 개요
세계의 감염증 면역측정 검사 시장 규모는 2025년에 88억 9,000만 달러로 추계되고 있으며, 2026년 91억 2,000만 달러에서 2033년까지 120억 3,000만 달러로 성장하며, 2026-2033년까지 CAGR은 4.02%에 달할 것으로 예측됩니다.
북미는 2025년에 47.75%라는 가장 높은 매출 점유율을 기록하며 전 세계 감염병 면역측정 검사 시장을 주도했습니다.
시장 역학
촉진요인: 감염병 유병률의 증가
감염병으로 인한 부담의 증가는 여전히 시장 성장을 지원하는 중요한 요인으로 작용하고 있습니다. 바이러스성, 세균성, 진균성 및 기생충성 감염증의 발생률이 증가함에 따라 전 세계 의료 현장에서 신속하고 정확한 면역측정법을 기반으로 한 진단 및 혈청학적 검사 솔루션에 대한 수요가 지속적으로 높아지고 있습니다. 세계보건기구(WHO)에 따르면 2024년에는 전 세계에서 약 1,070만 명이 결핵에 걸렸으며, 같은 해 결핵 관련 사망자 수는 123만 명에 육박했다고 보고되었습니다. 또한 유엔 에이즈 합동계획(UNAIDS)의 추산에 따르면 2025년에는 전 세계에서 약 4,008만 명이 HIV에 감염된 상태로 생활하고 있는 것으로 추정됩니다. 만성 감염증의 부담이 증가함에 따라 병원, 진단 검사실, 혈액은행, 공중보건 선별 검사 프로그램에서 ELISA, CLIA, 신속 항원 검사 및 항원·항체 병용 면역측정 기술의 도입이 확대되고 있습니다. 이에 따라 면역측정법을 활용한 감염증 진단 시장은 지속적인 성장을 달성하고 있습니다.
호흡기 감염증은 전 세계 감염증 검사 건수에서 여전히 큰 비중을 차지하고 있습니다. 미국 질병통제예방센터(CDC)에 따르면 2025년 호흡기 바이러스 유행 기간 중 미국 전역에서 인플루엔자 활동이 지속적으로 증가하고 있으며, 2025년 12월 현재 47개 주에서 인플루엔자 감염이 확산되고 있거나 확산될 가능성이 높은 것으로 나타났습니다. 또한 RSV(호흡기세포융합바이러스) 감염이 32개 주에서 증가하고 있거나 증가할 것으로 예상된다고 보고되었으며, 특히 0-4세 소아 사이에서 두드러지게 나타났습니다. 한편, 31개 주에서 COVID-19 감염자가 증가하고 있었습니다. 인플루엔자, RSV 및 COVID-19 감염이 지속됨에 따라 의료 현장 전반에서 면역측정법을 기반으로 한 감염병 검사에 대한 큰 계절적 수요가 발생하고 있습니다. 호흡기 바이러스 감염증의 유병률 증가에 따라 병원, 진료소, 진단 검사실에서 신속 항원 검사, 형광 면역 분석법 및 화학 발광 면역 분석법(CLIA) 시스템의 도입이 가속화되고 있습니다. 질병의 조기 발견, 호흡기 감염증 감시, 그리고 집단 발생 관리에 대한 관심이 높아지고 있는 것이 전 세계 감염증 면역측정 검사 산업의 성장을 더욱 촉진하고 있습니다.
성병 및 매개성 질환 역시 시장 성장에 기여하고 있습니다. WHO의 추산에 따르면 매독, 임질, 클라미디아, 트리코모나스증 등 치료 가능한 성병이 전 세계에서 매일 100만 건 이상 발생하고 있습니다. 성병 유병률의 증가와 HSV-2, 매독 등의 감염병으로 인한 부담이 커짐에 따라 진단 검사 기관, 혈액 은행, 공중보건 기관에서 항체 검사 및 항원·항체 병용 면역측정법에 대한 수요가 증가하고 있습니다. 또한 아시아태평양 지역과 라틴아메리카 전역에서 뎅기열 유행이 증가하고 있는 점이 다중 면역 분석법 및 신속 항원 검사 솔루션의 도입을 촉진하고 있습니다. 이와 동시에, 감염병 선별 검사 프로그램의 확대에 따라 전 세계 면역 검사 실시 건수는 계속해서 증가하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 감염증 면역측정 검사 시장 : 변수, 동향, 범위
제4장 감염증 면역측정 검사 시장 : 질환 유형별 비즈니스 분석
제5장 감염증 면역측정 검사 시장 : 기술별 비즈니스 분석
제6장 감염증 면역측정 검사 시장 : 테스트 유형별 비즈니스 분석
제7장 감염증 면역측정 검사 시장 : 최종 사용별 비즈니스 분석
제8장 감염증 면역측정 검사 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.06.26Infectious Disease Immunoassay Testing Market Summary
The global infectious disease immunoassay testing market size was estimated at USD 8.89 billion in 2025 and is projected to grow from USD 9.12 billion in 2026 to USD 12.03 billion by 2033, at a CAGR of 4.02% from 2026 to 2033. North America dominated the global infectious disease immunoassay testing market with the largest revenue share of 47.75% in 2025.
Market Dynamics
Drivers: Rising Prevalence of Infectious Diseases
The increasing burden of infectious diseases remains a significant factor supporting the market growth. The rising incidence of viral, bacterial, fungal, and parasitic infections continues to drive demand for rapid, accurate immunoassay-based diagnostic and serological testing solutions across healthcare settings globally. According to the World Health Organization, approximately 10.7 million people developed tuberculosis globally in 2024, while nearly 1.23 million tuberculosis-related deaths were reported during the year. Moreover, UNAIDS estimated that around 40.08 million people were living with HIV globally in 2025. The growing burden of chronic infectious diseases is driving greater adoption of ELISA, CLIA, rapid antigen tests, and combined antigen/antibody immunoassay technologies across hospitals, diagnostic laboratories, blood banks, and public health screening programs. This has further resulted in the continuous growth of immunoassay infectious diagnostics market.
Respiratory infectious diseases continue to account for a substantial share of global infectious disease testing volumes. According to the U.S. Centers for Disease Control and Prevention (CDC), influenza activity continued to increase across the United States during the 2025 respiratory virus season, with influenza infections growing or likely growing in 47 states as of December 2025. In addition, RSV infections were reported to be growing or likely growing in 32 states, particularly among children aged 0-4 years, while COVID-19 infections were increasing across 31 states. The continued circulation of influenza, RSV, and COVID-19 is generating significant seasonal demand for immunoassay-based infectious disease testing across healthcare settings. The rising prevalence of respiratory viral infections is accelerating the adoption of rapid antigen tests, fluorescent immunoassays, and chemiluminescence immunoassay (CLIA) systems across hospitals, physician offices, and diagnostic laboratories. The increasing focus on early disease detection, respiratory infection surveillance, and outbreak management is further supporting the global growth of the infectious disease immunoassay testing industry.
Sexually transmitted infections and vector-borne diseases are also contributing to the market growth. The WHO estimated that more than 1 million curable sexually transmitted infections are acquired every day globally, including syphilis, gonorrhea, chlamydia, and trichomoniasis. Rising STI prevalence and increasing burden of infections such as HSV-2 and syphilis are strengthening demand for antibody testing and combined antigen/antibody immunoassays across diagnostic laboratories, blood banks, and public health agencies. In addition, increasing dengue outbreaks across the Asia Pacific and Latin America are supporting the adoption of multiplex immunoassays and rapid antigen testing solutions. At the same time, the expansion of infectious disease screening programs continues to increase global immunoassay testing volumes.
Global Infectious Disease Immunoassay Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global infectious disease immunoassay testing market report based on disease type, technology, test type, technology, and region:
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Viral infections
- Bacterial infections
- Fungal infections
- Parasitic infections
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- ELISA
- CLIA
- Rapid antigen tests
- Fluorescent immunoassay
- Multiplex immunoassay
- Test Type Outlook (Revenue, USD Million, 2021 - 2033)
- Antigen testing
- Antibody testing
- Combined Ag/Ab tests
- Toxin assays
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic labs
- Physician offices
- Blood banks
- Public health agencies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disease Type
- 1.2.2. Technology
- 1.2.3. Test Type
- 1.2.4. End use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Infectious Disease Immunoassay Testing Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Infectious Disease Immunoassay Testing Market: Disease Type Business Analysis
- 4.1. Disease Type Market Share, 2025 & 2033
- 4.2. Disease Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
- 4.4. Viral infections
- 4.4.1. Viral infections Market, 2021 - 2033 (USD Million)
- 4.5. Bacterial infections
- 4.5.1. Bacterial infections Market, 2021 - 2033 (USD Million)
- 4.6. Fungal infections
- 4.6.1. Fungal infections Market, 2021 - 2033 (USD Million)
- 4.7. Parasitic infections
- 4.7.1. Parasitic infections Market, 2021 - 2033 (USD Million)
Chapter 5. Infectious Disease Immunoassay Testing Market: Technology Business Analysis
- 5.1. Technology Market Share, 2025 & 2033
- 5.2. Technology Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. ELISA
- 5.4.1. ELISA Market, 2021 - 2033 (USD Million)
- 5.5. CLIA
- 5.5.1. CLIA Market, 2021 - 2033 (USD Million)
- 5.6. Rapid antigen tests
- 5.6.1. Rapid antigen tests Market, 2021 - 2033 (USD Million)
- 5.7. Fluorescent immunoassay
- 5.7.1. Fluorescent immunoassay Market, 2021 - 2033 (USD Million)
- 5.8. Multiplex immunoassay
- 5.8.1. Multiplex immunoassay Market, 2021 - 2033 (USD Million)
Chapter 6. Infectious Disease Immunoassay Testing Market: Test Type Business Analysis
- 6.1. Test Type Market Share, 2025 & 2033
- 6.2. Test Type Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
- 6.4. Antigen testing
- 6.4.1. Antigen testing Market, 2021 - 2033 (USD Million)
- 6.5. Antibody testing
- 6.5.1. Antibody testing Market, 2021 - 2033 (USD Million)
- 6.6. Combined Ag/Ab tests
- 6.6.1. Combined Ag/Ab tests Market, 2021 - 2033 (USD Million)
- 6.7. Toxin assays
- 6.7.1. Toxin assays Market, 2021 - 2033 (USD Million)
Chapter 7. Infectious Disease Immunoassay Testing Market: End Use Business Analysis
- 7.1. End Use Market Share, 2025 & 2033
- 7.2. End Use Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, By End Use, 2021 to 2033 (USD Million)
- 7.4. Hospitals
- 7.4.1. Hospitals Market, 2021 - 2033 (USD Million)
- 7.5. Diagnostic labs
- 7.5.1. Diagnostic labs Market, 2021 - 2033 (USD Million)
- 7.6. Physician offices
- 7.6.1. Physician offices Market, 2021 - 2033 (USD Million)
- 7.7. Blood banks
- 7.7.1. Blood banks Market, 2021 - 2033 (USD Million)
- 7.8. Public health agencies
- 7.8.1. Public health agencies Market, 2021 - 2033 (USD Million)
Chapter 8. Infectious Disease Immunoassay Testing Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Infectious Disease Immunoassay Testing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Infectious Disease Immunoassay Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Abbott
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Siemens Healthineers
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Danaher Corporation
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. bioMerieux SA
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Quidel Corporation
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Ortho Clinical Diagnostics
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Sysmex Corporation
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Bio-Rad Laboratories, Inc.
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. F. Hoffmann-La Roche AG
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Becton, Dickinson, and Company
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
- 9.5.11. Thermo Fisher Scientific, Inc.
- 9.5.11.1. Overview
- 9.5.11.2. Financial Performance
- 9.5.11.3. Product Benchmarking
- 9.5.11.4. Strategic Initiatives
- 9.5.1. Abbott
(주말 및 공휴일 제외)
